Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:alvocidib
go back to main search page
Accession:CHEBI:47344 term browser browse the term
Definition:A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.
Synonyms:related_synonym: (-)-cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one;   2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-chromen-4-one;   Flavopiridol;   Formula=C21H20ClNO5;   HMR-1274;   InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1;   InChIKey=BIIVYFLTOXDAOV-YVEFUNNKSA-N;   L 86-8275;   L 868275;   L86-8275;   SMILES=C=12OC(=CC(C1C(=CC(=C2[C@@H]3[C@@H](CN(CC3)C)O)O)O)=O)C4=C(C=CC=C4)Cl;   alvocidibum
 xref: CAS:146426-40-6;   DrugBank:DB03496;   KEGG:D09868;   LINCS:LSM-1011
 xref_mesh: MESH:C077990
 xref: PDBeChem:CPB;   PMID:10441105;   PMID:1279187;   PMID:18209094;   PMID:21541623;   PMID:23959599;   PMID:25118834;   PMID:25216351;   PMID:25351763;   PMID:25623777;   PMID:25860066;   PMID:25989942;   PMID:26022709;   PMID:26521988;   PMID:26599132;   PMID:8002990;   PMID:9269999;   PMID:9815683;   Patent:EP241003;   Patent:US4900727;   Wikipedia:Alvocidib
 cyclic_relationship: is_conjugate_base_of CHEBI:90997


show annotations for term's descendants           Sort by:
 
alvocidib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein CTD PMID:15039284 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 increases localization ISO alvocidib results in increased localization of AIFM1 protein CTD PMID:12734434 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form CTD PMID:15039284 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of BAD protein CTD PMID:12231544 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bag1 BAG cochaperone 1 decreases expression ISO alvocidib results in decreased expression of BAG1 mRNA; alvocidib results in decreased expression of BAG1 protein; alvocidib results in decreased expression of BAG1 protein alternative form CTD PMID:10887097, PMID:15972445 NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects localization
increases cleavage
increases expression
multiple interactions
ISO alvocidib affects the localization of BAX protein
alvocidib results in increased cleavage of BAX protein
alvocidib results in increased expression of BAX protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of BAX protein; [alvocidib co-treated with gemcitabine] results in increased expression of BAX protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein; Epothilones promotes the reaction [alvocidib affects the localization of BAX protein]
CTD PMID:12517783, PMID:12589031, PMID:12734434, PMID:15634644, PMID:15770523, PMID:16951203 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
decreases response to substance
multiple interactions
increases expression
ISO alvocidib results in decreased expression of BCL2 mRNA; alvocidib results in decreased expression of BCL2 protein
BCL2 protein mutant form results in decreased susceptibility to alvocidib; BCL2 protein results in decreased susceptibility to alvocidib
[alvocidib co-treated with gemcitabine] results in decreased expression of BCL2 protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein]; BCL2 protein results in decreased susceptibility to [alvocidib co-treated with Epothilones]
alvocidib results in increased expression of BCL2
CTD PMID:10887097, PMID:10995888, PMID:12170773, PMID:12517783, PMID:12589031, PMID:12734434, PMID:15770523, PMID:15972445 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of BCL2L1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 protein]
alvocidib results in decreased expression of BCL2L1; alvocidib results in decreased expression of BCL2L1 mRNA; alvocidib results in decreased expression of BCL2L1 protein
CTD PMID:12517783, PMID:15039284, PMID:15634644, PMID:16820931 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage
ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of BID protein; [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of BID protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of BID protein] CTD PMID:11464216, PMID:12170773, PMID:12231544, PMID:15634644, PMID:16951203 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
multiple interactions
ISO alvocidib results in decreased expression of BIRC3 mRNA; alvocidib results in decreased expression of BIRC3 protein
Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 protein]
CTD PMID:12517783 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [alvocidib co-treated with 7-hydroxystaurosporine] results in decreased expression of BIRC5 protein; [alvocidib co-treated with PBOX-6] results in decreased expression of BIRC5 protein; alvocidib inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of BIRC5 protein]; alvocidib results in decreased phosphorylation of and results in decreased expression of BIRC5 protein
alvocidib results in decreased expression of BIRC5; alvocidib results in decreased expression of BIRC5 mRNA; alvocidib results in decreased expression of BIRC5 protein
CTD PMID:12517783, PMID:12517802, PMID:16012789, PMID:16820931, PMID:20206141 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Btg2 BTG anti-proliferation factor 2 increases expression ISO alvocidib results in increased expression of BTG2 mRNA CTD PMID:21382384 NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
JBrowse link
G Casp3 caspase 3 affects cleavage
multiple interactions
increases cleavage
increases activity
ISO
EXP
alvocidib affects the cleavage of CASP3 protein
alvocidib inhibits the reaction [Colchicine results in increased activity of CASP3 protein]
alvocidib results in increased cleavage of CASP3 protein
alvocidib results in increased activity of CASP3 protein
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased activity of CASP3 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP3 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of CASP3 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP3 protein; [irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; alvocidib affects the cleavage of and results in increased activity of CASP3 protein; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [romidepsin results in increased activity of CASP3 protein]; alvocidib results in increased cleavage of and results in increased activity of CASP3 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of and results in increased activity of CASP3 protein]
CTD PMID:9808574, PMID:10430095, PMID:10896673, PMID:11482875, PMID:11751522, PMID:12170773, PMID:12231544, PMID:12517783, PMID:12589031, PMID:12941380, PMID:14555534, PMID:15014036, PMID:15634644, PMID:15770523, PMID:16012789 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP8 protein
alvocidib results in increased cleavage of CASP8 protein
CTD PMID:10896673, PMID:12231544, PMID:12589031, PMID:15634644, PMID:16012789, PMID:16951203 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 affects cleavage
increases activity
multiple interactions
ISO alvocidib affects the cleavage of CASP9 protein
alvocidib results in increased activity of CASP9 protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP9 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]
CTD PMID:10896673, PMID:12170773, PMID:15634644 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cbr3 carbonyl reductase 3 decreases expression ISO alvocidib results in decreased expression of CBR3 mRNA CTD PMID:21382384 NCBI chr11:33,909,417...33,917,674
Ensembl chr11:33,909,439...33,917,674
JBrowse link
G Ccna2 cyclin A2 multiple interactions ISO alvocidib results in decreased expression of and results in decreased activity of CCNA2 protein CTD PMID:16731754 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
decreases expression
ISO [alvocidib co-treated with PBOX-6] results in decreased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; alvocidib results in decreased expression of and results in decreased activity of CCNB1 protein
alvocidib results in decreased expression of CCNB1 protein
CTD PMID:10430095, PMID:12517783, PMID:15014036, PMID:16731754, PMID:20206141 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of CCND1 protein
alvocidib results in decreased expression of CCND1 protein
alvocidib results in decreased activity of CCND1 protein
CTD PMID:9802881, PMID:9829756, PMID:10441105, PMID:12517783, PMID:12589031, PMID:12734434, PMID:15634644, PMID:16905211 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccne1 cyclin E1 decreases expression ISO alvocidib results in decreased expression of CCNE1 protein CTD PMID:15014036 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with PBOX-6] results in decreased activity of CDK1 protein
alvocidib results in decreased expression of CDK1 protein modified form
alvocidib results in decreased activity of CDK1 protein
CTD PMID:9427698, PMID:9802881, PMID:12517783, PMID:16905211, PMID:20206141 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression
decreases activity
multiple interactions
ISO alvocidib results in decreased expression of CDK2 protein modified form
alvocidib results in decreased activity of CDK2 protein
alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein]
CTD PMID:9802881, PMID:10430095, PMID:12517783, PMID:16905211 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases activity
decreases expression
ISO alvocidib results in decreased activity of CDK4 protein
alvocidib results in decreased expression of CDK4 protein
CTD PMID:12517783, PMID:12734434 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk5 cyclin-dependent kinase 5 multiple interactions EXP alvocidib inhibits the reaction [Colchicine results in increased expression of CDK5 protein] CTD PMID:12941380 NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
decreases expression
increases cleavage
increases expression
affects expression
ISO [alvocidib co-treated with gemcitabine] results in increased expression of CDKN1A protein; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A promoter]; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]]
alvocidib results in decreased expression of CDKN1A protein
alvocidib results in increased cleavage of CDKN1A protein
alvocidib results in increased expression of CDKN1A protein
alvocidib affects the expression of CDKN1A protein
CTD PMID:10537362, PMID:12734434, PMID:15014036, PMID:15180955, PMID:15770523 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases cleavage
increases expression
ISO alvocidib results in increased cleavage of CDKN1B protein
[alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of CDKN1B protein
CTD PMID:10537362, PMID:12589031, PMID:15180955 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases expression
ISO alvocidib affects the expression of CFLAR mRNA
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein]
alvocidib results in decreased expression of CFLAR; alvocidib results in decreased expression of CFLAR protein
CTD PMID:16820931, PMID:16951203 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Cycs cytochrome c, somatic affects localization
multiple interactions
ISO alvocidib affects the localization of CYCS protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of CYCS protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]
CTD PMID:12170773, PMID:12517783, PMID:15634644 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
multiple interactions
ISO alvocidib affects the localization of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of DIABLO protein; [Imatinib Mesylate co-treated with alvocidib] results in increased secretion of DIABLO protein
CTD PMID:12231544, PMID:12517783, PMID:15039284, PMID:15634644 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G E2f1 E2F transcription factor 1 increases expression
increases response to substance
decreases expression
ISO alvocidib results in increased expression of E2F1 protein
E2F1 results in increased susceptibility to alvocidib
alvocidib results in decreased expression of E2F1 mRNA
CTD PMID:12533675, PMID:21239698 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G H2ax H2A.X variant histone affects expression ISO alvocidib affects the expression of H2AX protein CTD PMID:15078984 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Hmga1 high mobility group AT-hook 1 decreases expression ISO alvocidib results in decreased expression of HMGA1 mRNA CTD PMID:21239698 NCBI chr20:7,132,501...7,140,155
Ensembl chr20:7,136,007...7,138,980
JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO alvocidib affects the localization of HTRA2 protein CTD PMID:12517783 NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] CTD PMID:23589332 NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
JBrowse link
G Isg15 ISG15 ubiquitin-like modifier multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] CTD PMID:23589332 NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [Imatinib Mesylate co-treated with alvocidib] results in increased activity of JUN protein CTD PMID:12231544 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases expression
decreases phosphorylation
ISO alvocidib results in decreased expression of KIT mRNA; alvocidib results in decreased expression of KIT promoter
alvocidib results in decreased phosphorylation of KIT protein
CTD PMID:16740725 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein] CTD PMID:15039284 NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK1 protein CTD PMID:15014036, PMID:15039284 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK14 protein CTD PMID:15634644 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK3 protein CTD PMID:15014036, PMID:15039284 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK8 protein; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein] CTD PMID:15039284, PMID:15634644 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member affects expression
decreases response to substance
decreases expression
multiple interactions
ISO alvocidib affects the expression of MCL1 mRNA; alvocidib affects the expression of MCL1 protein
MCL1 results in decreased susceptibility to alvocidib
alvocidib results in decreased expression of MCL1 mRNA; alvocidib results in decreased expression of MCL1 protein
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of MCL1 protein; [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of MCL1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 protein]
CTD PMID:10887097, PMID:12231544, PMID:12429644, PMID:12517783, PMID:12533675, PMID:15634644, PMID:15972445 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mdm2 MDM2 proto-oncogene decreases expression ISO alvocidib results in decreased expression of MDM2 mRNA; alvocidib results in decreased expression of MDM2 protein CTD PMID:12589031 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Mx2 MX dynamin like GTPase 2 multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] CTD PMID:23589332 NCBI chr11:38,035,306...38,066,185
Ensembl chr11:38,035,450...38,059,950
JBrowse link
G Nelfa negative elongation factor complex member A multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]] CTD PMID:23589332 NCBI chr14:82,093,837...82,117,913
Ensembl chr14:82,093,837...82,117,906
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression
multiple interactions
ISO alvocidib results in increased expression of NFKBIA protein modified form
alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]
CTD PMID:15039284 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO alvocidib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] CTD PMID:25257666 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of PARP1 protein; [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of PARP1 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of PARP1 protein; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein] CTD PMID:10430095, PMID:12170773, PMID:12517783, PMID:15039284, PMID:15634644, PMID:15770523, PMID:15972445, PMID:16012789, PMID:20663931 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pawr pro-apoptotic WT1 regulator multiple interactions EXP alvocidib inhibits the reaction [Colchicine results in increased expression of PAWR protein] CTD PMID:12941380 NCBI chr 7:51,273,764...51,353,700
Ensembl chr 7:51,273,771...51,353,068
JBrowse link
G Pcna proliferating cell nuclear antigen decreases activity ISO alvocidib results in decreased activity of PCNA protein CTD PMID:10441105 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Perp p53 apoptosis effector related to PMP22 increases expression ISO alvocidib results in increased expression of PERP mRNA CTD PMID:21382384 NCBI chr 1:14,224,392...14,236,838
Ensembl chr 1:14,224,393...14,236,846
JBrowse link
G Polr2a RNA polymerase II subunit A decreases expression
decreases phosphorylation
multiple interactions
ISO alvocidib results in decreased expression of POLR2A mRNA
alvocidib results in decreased phosphorylation of POLR2A protein
Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]
CTD PMID:15039284, PMID:21239698, PMID:23589332 NCBI chr10:56,339,277...56,364,888
Ensembl chr10:56,339,284...56,365,084
JBrowse link
G Pygb glycogen phosphorylase B affects binding ISO PYGB protein binds to alvocidib CTD PMID:11368340 NCBI chr 3:146,581,063...146,629,504
Ensembl chr 3:146,582,752...146,634,535
JBrowse link
G Pygl glycogen phosphorylase L affects binding ISO PYGL protein binds to alvocidib CTD PMID:11368340 NCBI chr 6:92,597,759...92,643,734
Ensembl chr 6:92,597,706...92,643,847
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases activity
decreases response to substance
multiple interactions
decreases phosphorylation
decreases expression
ISO alvocidib results in decreased activity of RB1 protein modified form
RB1 results in decreased susceptibility to alvocidib
[docetaxel co-treated with alvocidib] results in decreased phosphorylation of and results in decreased expression of RB1 protein
alvocidib results in decreased phosphorylation of RB1 protein
alvocidib results in decreased expression of RB1 protein; alvocidib results in decreased expression of RB1 protein modified form
CTD PMID:9829756, PMID:10441105, PMID:15180955, PMID:15297405, PMID:16905211 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rbl1 RB transcriptional corepressor like 1 decreases expression ISO alvocidib results in decreased expression of RBL1 protein CTD PMID:9829756 NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
decreases expression
ISO [alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein
alvocidib results in decreased expression of STAT3 mRNA
CTD PMID:15039284, PMID:21239698 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Supt5h SPT5 homolog, DSIF elongation factor subunit multiple interactions ISO alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] CTD PMID:23589332 NCBI chr 1:85,437,780...85,466,854
Ensembl chr 1:85,437,780...85,466,854
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO alvocidib analog results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO alvocidib inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] CTD PMID:21204955 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b increases expression ISO alvocidib results in increased expression of TNFRSF10A CTD PMID:16820931 NCBI chr15:51,433,853...51,464,215 JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases response to substance
increases expression
ISO [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein
alvocidib results in increased susceptibility to TNFSF10
alvocidib results in increased expression of TNFSF10
CTD PMID:16820931, PMID:16951203 NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
JBrowse link
G Tp53 tumor protein p53 decreases expression
multiple interactions
increases expression
ISO alvocidib results in decreased expression of TP53 protein
[docetaxel co-treated with alvocidib] results in increased expression of TP53 protein
[alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of TP53 protein
CTD PMID:9808574, PMID:10537362, PMID:12589031, PMID:15180955, PMID:15297405 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO alvocidib results in decreased expression of VEGFA mRNA CTD PMID:21239698 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
multiple interactions
ISO alvocidib results in decreased expression of XIAP mRNA; alvocidib results in decreased expression of XIAP protein
[irinotecan co-treated with alvocidib] results in increased cleavage of XIAP protein; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP protein]
CTD PMID:10887097, PMID:11751522, PMID:12517783, PMID:15385934, PMID:15972445, PMID:16951203 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      biological role 19732
        biochemical role 19281
          apoptosis inducer 10893
            alvocidib 68
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic molecule 19486
                              organic cyclic compound 19282
                                organic heterocyclic compound 18407
                                  oxacycle 17181
                                    benzopyran 10132
                                      1-benzopyran 9848
                                        flavonoid 6372
                                          flavones 4166
                                            hydroxyflavone 4154
                                              dihydroxyflavone 474
                                                alvocidib 68
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.